LoadingLoadingLoadingNo insider open-market trades in 90 days (SEC Form 4). Congress: net selling of $15K to $50K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (3)
Millennium
$118.8M
bought
Farallon Capital
$56.9M
bought
Citadel
$50.3M
bought
Sells (1)
No tracked top-trader positions in NVS as of Oct 24, 07:01 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Jul 21, 2026
Period ending
Jun 30, 2026
Earnings per share
$2.15 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$2.22 to $2.26
Revenue expected
8 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 21, 2026 | $2.41 / $2.15Yahoo Finance | +12.21% beat | $14.42B No estimate | Unavailable |
| Mar 31, 2026 | Apr 28, 2026 | $1.99 / $2.07Yahoo Finance | -3.68% miss | $13.52B No estimate | Unavailable |
| Dec 31, 2025 | Feb 4, 2026 | $2.03 / $2.00Yahoo Finance | +1.27% beat | $13.33B No estimate | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $2.25 / $2.31Yahoo Finance | -2.63% miss | $14.36B No estimate | Unavailable |
| Jun 30, 2025 | Jul 17, 2025 | $2.42 / $2.37Alpha Vantage | +2.11% beat | $14.84B No estimate | Unavailable |
| Mar 31, 2025 | Apr 29, 2025 | $2.28 / $2.17Alpha Vantage | +5.07% beat | $13.62B No estimate | Unavailable |
| Dec 31, 2024 | Jan 31, 2025 | $1.98 / $1.76Alpha Vantage | +12.50% beat | $13.56B No estimate | Unavailable |
| Sep 30, 2024 | Oct 29, 2024 | $2.06 / $1.93Alpha Vantage | +6.74% beat | $13.17B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $14.36B | $13.33B | $13.52B | $14.42B |
| Cost of what it sold | $3.54B | $3.54B | $3.46B | $3.68B |
| Gross profit | $10.82B | $9.79B | $10.06B | $10.74B |
| What it spent | ||||
| Research and development | $2.94B | $2.84B | $2.74B | $2.76B |
| Sales and admin | $3.31B | $3.44B | $3.14B | $3.24B |
| Other operating costs | $66.0M | — | — | — |
| Total operating expenses | $6.32B | $6.27B | $5.83B | $6.00B |
| What was left | ||||
| Operating profit | $4.50B | $3.52B | $4.24B | $4.74B |
| Interest on debt | $281.0M | $304.0M | $343.0M | $462.3M |
| Profit before tax | $4.20B | $3.22B | $3.84B | $4.27B |
| Tax | $266.0M | $813.9M | $683.0M | $1.01B |
| Net profit | $3.93B | $2.41B | $3.16B | $3.27B |
| EBITDA | $5.84B | $5.07B | $5.41B | $5.94B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
Earnings Preview: Novartis AG to Report Financial Results on October 27
Leans bullishOct 22Novartis (NVS) Gains European Commission Approval for Cosentyx in Polymyalgia Rheumatica
BullishOct 21Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
BullishOct 21Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
BullishOct 21Novartis ranks #19 in TIME and Statista’s World’s Best Companies 2026
BullishOct 21Novartis AG (NVS) Options Chain - Yahoo Finance
Leans bullishOct 20An employee smokes a cigarette beside the logo of Swiss drugmaker Novartis AG in front of a plant in Basel
BearishOct 20Licensable picture: A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel
NeutralOct 20
